Monthly production to see surge: Covishield to reach 120 million, Covaxin to 58 million per month

Last updated on August 9th, 2021 at 10:03 am

‘Mission COVID Suraksha- the Indian COVID-19 Vaccine Development Mission’ has been launched by Department of Biotechnology under the Ministry of Science and Technology.

The initiative has been launched with sole aim of supporting vaccine production in India. The Mission is being implemented by the Biotechnology Industry Research Assistance Council (BIRAC), which is a public sector undertaking (PSU) of the Department of Biotechnology. 

Covishield’s monthly production is projected to increase to over 120 million doses while that of Covaxin will increase to 58 million doses by month of December. The information was told in Rajya Sabha by the government on Tuesday. 

Union Health Minister Mansukh Mandaviya said, “As communicated by the manufacturers, the monthly vaccine production capacity of Covishield is projected to be increased from 110 million doses per month to more than 120 million doses per month and the production capacity of Covaxin is projected to be increased from 25 million doses per month to around 58 million doses per month.” The minister was responding to questions on current vaccine production capacity in the country.

Related Posts

• After some shocking exits, Lovlina, Kamapreet stand out at the Tokyo Games with their solid performance
• After the Divorce announcement, Aamir Khan, Kiran Rao sit down for a message
• As ‘Covaxin’ gets a nod from WHO, India expects more nations to give emergency approval
• BTS will be returning to ‘The Tonight Show’ with their new single ‘Permission to Dance’
• Covaxin Efficacy Determined At 50Percent: First World Study
• Oppo launches new Under Screen Camera technology for selfie lovers
• Supreme Court Hold Facebook Responsible For Instigating Public Outrage Here And There

Under the Mission, facility ramping would be done of Bharat Biotech and one state public sector enterprise and 2 central public sector enterprises (PSEs) – Haffkine Biopharmaceutical Corporation Ltd, Mumbai; Indian Immunologicals Limited (IIL), Hyderabad and Bharat Immunologicals Biologicals Limited (BIBCOL), Bulandshahr – for production of Covaxin.

Additionally, technology transfer of Covaxin production to Gujarat COVID Vaccine Consortium (GCVC) would be done, including Hester Biosciences and OmniBRx Biotechnologies Pvt Ltd, led by Gujarat Biotechnology Research Centre (GBRC) of Department of Science and Technology, Government of Gujarat. 

“At risk manufacturing” of the Covid-19 vaccine will also be enabled through financial assistance through domestic manufacturers of the vaccine. Furthermore, financial assistance will also be extended to advance payment for supply orders with Bharat Biotech and Serum Institute of India.